Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis
Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis
复制标题
索拉非尼治疗日本转移性肾细胞癌血液透析患者的疗效和安全性
DOI：
--
复制
发表时间：
2016
影响因子：
3.3
通讯作者：
K. Tanabe
中科院分区：
文献类型：
--
作者：
K. Omae;T. Kondo;Takafumi Kennoki;T. Takagi;J. Iizuka;Hirohito Kobayashi;Y. Hashimoto;K. Tanabe
背景很少有关于使用酪氨酸激酶抑制剂治疗血液透析（HD）患者的资料。我们调查了索拉非尼的疗效和安全性转移性肾细胞癌（mRCC）患者接受HD.MethodsTwenty接受HD患者索拉非尼作为一线治疗mRCC在我院2008年4月至2014年8月。患者的医疗记录进行了回顾性审查，以评估索拉非尼和治疗相关的toxicity.Results15和5例患者被分类在中间和穷人的风险组，分别纪念斯隆-凯特琳癌症中心的风险模型。18例患者有3个或更多转移病灶，7例患者有2个或更多器官转移。在16例既往接受过肾切除术的患者中，8例病理诊断为非透明细胞癌。索拉非尼治疗的中位持续时间为4.7个月。15例患者因疾病进展而停用索拉非尼，4例患者因严重不良事件（AE）（≥ 3级）而停用索拉非尼，即蛛网膜下腔出血、脑出血、脓毒症和晕厥各1例患者。中位进展时间为6.3个月，中位总生存期为14.2 months.ConclusionsIn这项研究中，许多患者有不利的临床特征，例如不良的风险分类和多器官转移。尽管索拉非尼治疗HD患者似乎是可行的，但由于严重AE的发生率较高，因此需要进行仔细监测，即使在降低剂量时也是如此。
BackgroundLittle information has been published on the use of tyrosine kinase inhibitors for treatment of patients undergoing hemodialysis (HD). We investigated the efficacy and safety of sorafenib for metastatic renal cell carcinoma (mRCC) patients undergoing HD.MethodsTwenty patients undergoing HD were treated with sorafenib as first-line therapy for mRCC at our hospital between April 2008 and August 2014. Patient medical records were retrospectively reviewed to evaluate the response to sorafenib and treatment-related toxicity.ResultsFifteen and 5 patients were classified in the intermediate and poor risk groups, respectively, of the Memorial Sloan–Kettering Cancer Center risk model. Eighteen patients had 3 or more metastatic lesions, and 7 patients had metastases in 2 or more organs. Of 16 patients who had previously undergone nephrectomy, 8 were pathologically diagnosed with non-clear-cell carcinoma. The median duration of sorafenib therapy was 4.7 months. Sorafenib was discontinued owing to progressing disease for 15 patients and because of serious adverse events (AE) (≥grade 3) for 4 patients, i.e. subarachnoid hemorrhage, cerebral hemorrhage, sepsis, and syncope for 1 patient each. Median time to progression was 6.3 months, and median overall survival was 14.2 months.ConclusionsIn this study, many patients had unfavorable clinical features, for example poor risk classification and metastases in multiple organs. Although sorafenib treatment of HD patients seems feasible, careful monitoring is needed because of the tendency for a high incidence of serious AE, even when a reduced dose is administered.
影响因子：
45.3
作者：
Motzer, RJ;Bacik, J;Mazumdar, M
通讯作者：
Mazumdar, M
DOI：
10.1097/01.asn.0000019641.41496.1e
发表时间：
2002-07-01
影响因子：
13.6
作者：
Longenecker, JC;Coresh, J;Klag, MJ
通讯作者：
Klag, MJ